Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimization of CCR4 antagonists: side-chain exploration.

Ashok V Purandare1, Honghe Wan, Aiming Gao

  • 1Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543, USA. ashok.purandare@bms.com

Bioorganic & Medicinal Chemistry Letters
|October 21, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drug Delivery Strategy Exploiting Amino Acid Prodrugs: Improving Oral Bioavailability and Overcoming Nonlinear Pharmacokinetic Challenges Following Dose Escalation of a CK2 Inhibitor with Poor Solubility.

Journal of medicinal chemistry·2026
Same author

Discovery of BMS-159, an Orally Active Imidazotriazine Pan-CK2 Inhibitor for the Treatment of Cancer.

ACS medicinal chemistry letters·2026
Same author

Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C.

Nature communications·2026
Same author

Enhancing the Oral Bioavailability of a Poorly Soluble Pan-CK2 Kinase Inhibitor: Leveraging a Phosphate Prodrug Strategy to Overcome Dissolution-Limited Absorption and Improve Systemic Exposure during Dose Escalation.

Journal of medicinal chemistry·2026
Same author

Assessing Potential Benefit of a Paediatric Short Stay Unit at a Secondary Hospital in Western Australia.

Sage open pediatrics..·2025
Same author

Specific phobias in children with moderate to severe intellectual disabilities: SPIRIT, an adaptation and feasibility study.

Health technology assessment (Winchester, England)·2024

Researchers designed novel small molecule antagonists targeting CC chemokine receptor-4 (CCR4). Compound 8c demonstrated efficacy in a mouse model of allergic inflammation, suggesting therapeutic potential.

Area of Science:

  • Medicinal Chemistry
  • Immunology
  • Pharmacology

Background:

  • CC chemokine receptor-4 (CCR4) is implicated in allergic inflammation and immune responses.
  • Targeting CCR4 offers a potential therapeutic strategy for inflammatory diseases.

Purpose of the Study:

  • To design, synthesize, and evaluate novel small molecule antagonists of CCR4.
  • To assess the in vivo efficacy of these antagonists in an allergic inflammation model.

Main Methods:

  • Small molecule design and synthesis.
  • In vitro characterization of CCR4 antagonism.
  • In vivo testing in a murine allergic inflammation model.

Main Results:

  • Novel and selective small molecule CCR4 antagonists were successfully designed and synthesized.

Related Experiment Videos

  • Compound 8c exhibited significant efficacy in a murine model of allergic inflammation.
  • The effective dose 50 (ED50) for Compound 8c was determined to be 30 mg/kg.

    • Conclusions:

    • The developed small molecules are potent and selective CCR4 antagonists.
    • Compound 8c shows promise as a therapeutic agent for allergic inflammatory conditions.